{"id":"https://openalex.org/W2274859418","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2057","title":"Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.","display_name":"Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2274859418","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2057","mag":"2274859418"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.2057","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2057","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.2057","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026869480","display_name":"Tobias Walbert","orcid":"https://orcid.org/0000-0003-0667-8106","observed_orcids":["https://orcid.org/0000-0003-0667-8106"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Walbert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109054807","display_name":"MARCEL R. GILBERT","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. R. Gilbert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110346854","display_name":"Morris D. Groves","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. D. Groves","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037535298","display_name":"Vinay K. Puduvalli","orcid":"https://orcid.org/0000-0001-8396-9500","observed_orcids":["https://orcid.org/0000-0001-8396-9500"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. K. Puduvalli","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001098802","display_name":"WK Alfred Yung","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. A. Yung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106083527","display_name":"Charles A. Conrad","orcid":"https://orcid.org/0000-0001-5178-8465","observed_orcids":["https://orcid.org/0000-0001-5178-8465"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. A. Conrad","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067903216","display_name":"George C. Bobustuc","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. C. Bobustuc","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047608444","display_name":"Howard Colman","orcid":"https://orcid.org/0000-0002-4027-7317","observed_orcids":["https://orcid.org/0000-0002-4027-7317"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Colman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111432852","display_name":"Benjamin Nebiyou Bekele","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. N. Bekele","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5083356663","display_name":"V. A. Levin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. A. Levin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"2057","last_page":"2057"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/recurrent-high-grade-glioma","display_name":"recurrent high-grade glioma","score":0.8240000009536743},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9150000214576721},{"id":"https://openalex.org/keywords/anaplastic-glioma","display_name":"anaplastic glioma","score":0.996999979019165},{"id":"https://openalex.org/keywords/6-thioguanine","display_name":"6-thioguanine","score":0.9259999990463257},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":1.0},{"id":"https://openalex.org/keywords/celecoxib","display_name":"celecoxib","score":1.0},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/lomustine","display_name":"lomustine","score":0.9909999966621399},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.875},{"id":"https://openalex.org/keywords/alkylating-agents","display_name":"alkylating agents","score":0.968999981880188},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9779999852180481},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.765999972820282},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.8740000128746033},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.4490000009536743}],"concepts":[{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.9344391822814941},{"id":"https://openalex.org/C2779434656","wikidata":"https://www.wikidata.org/wiki/Q415378","display_name":"Lomustine","level":5,"score":0.9112123250961304},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.886272132396698},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7040379047393799},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.7001979947090149},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5967360734939575},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5868505239486694},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.5355375409126282},{"id":"https://openalex.org/C2776946711","wikidata":"https://www.wikidata.org/wiki/Q418311","display_name":"Nitrosourea","level":3,"score":0.5316420793533325},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.4881516098976135},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4572772979736328},{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.42844802141189575},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41238248348236084},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3419639766216278},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3260989487171173},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.30501604080200195},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.2122250199317932},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.12047386169433594},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.09832197427749634},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.052975744009017944}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.2057","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2057","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.2057","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2898356742","https://openalex.org/W2536704472","https://openalex.org/W2419451702","https://openalex.org/W2159378961","https://openalex.org/W2058747986","https://openalex.org/W2032862134","https://openalex.org/W2972136877","https://openalex.org/W32372490","https://openalex.org/W2007491396","https://openalex.org/W2313539751"],"abstract_inverted_index":{"2057":[0],"Background:":[1],"There":[2],"is":[3,18,252],"currently":[4],"no":[5,131],"standardized":[6],"therapy":[7,222],"for":[8,15,92,99,244,254],"high-grade":[9],"gliomas":[10],"after":[11],"recurrence.":[12],"Since":[13],"chemotherapy":[14,30],"these":[16],"tumors":[17],"still":[19],"dominated":[20],"by":[21],"alkylating":[22,242],"agents,":[23],"we":[24],"evaluated":[25],"the":[26,116,125,144,150,154,158,170,183,187,198],"efficacy":[27],"of":[28,104],"combination":[29,221],"with":[31,48,55,70,94,101,139,143,217,223,246,256],"temozolomide":[32],"(TMZ)":[33],"or":[34,231,262,266],"lomustine":[35],"(CCNU)":[36],"and":[37,42,52,84,96,106,118,147,163,176,193,214,226],"6-thioguanine":[38],"(6-TG),":[39],"capecitabine":[40],"(CAP),":[41],"celecoxib":[43],"(CEL).":[44],"Methods:":[45],"Forty-three":[46],"patients":[47,54,80,93,100,138,245,255],"recurrent":[49,56,247,257],"glioblastoma":[50],"(GBM)":[51],"31":[53,184],"anaplastic":[57],"glioma":[58],"(AG)":[59],"were":[60,87,122,141],"enrolled":[61],"in":[62,124],"this":[63],"open-label,":[64],"non-comparative,":[65],"study.":[66],"Patients":[67],"previously":[68],"treated":[69,142],"TMZ":[71,117,232],"received":[72,77,81,149],"CCNU":[73,119,230],"while":[74],"all":[75,79],"others":[76],"TMZ;":[78],"6-TG,":[82,224],"CAP,":[83,225],"CEL.":[85],"Endpoints":[86],"12-month":[88],"progression-free":[89],"survival":[90,179],"(PFS)":[91],"AG":[95,185],"6-month":[97],"PFS":[98,173,201],"GBM,":[102,169],"duration":[103],"PFS,":[105],"MRI-":[107],"based":[108],"objective":[109],"response":[110],"rates":[111],"(OR).":[112],"Results:":[113],"Results":[114],"from":[115],"treatment":[120],"arms":[121],"combined":[123,188],"final":[126],"analysis":[127],"because":[128],"there":[129],"was":[130,161,174,191,202,205,211],"statistically":[132],"significant":[133],"difference":[134],"between":[135],"them.":[136],"38":[137],"GBM":[140,156],"CCNU-based":[145],"regimen,":[146],"5":[148],"TMZ-based":[151],"regimen.":[152],"For":[153,168,182],"43":[155],"patients,":[157,186],"OR":[159,189],"rate":[160,190],"12%":[162],"33%":[164],"had":[165,195],"stable":[166,196],"disease.":[167],"6":[171],"month":[172,200],"14%":[175],"median":[177],"overall":[178],"32":[180],"weeks.":[181],"26%":[192],"42%":[194],"disease;":[197],"12":[199],"44%.":[203],"Treatment":[204],"reasonably":[206],"well":[207],"tolerated;":[208],"hematologic":[209],"toxicity":[210],"most":[212],"common":[213],"more":[215,238],"frequent":[216],"CCNU.":[218],"Conclusions:":[219],"The":[220,249],"CEL":[227],"plus":[228],"either":[229],"does":[233],"not":[234],"appear":[235],"to":[236],"be":[237],"effective":[239],"than":[240],"conventional":[241],"agents":[243],"GBM.":[248],"combination,":[250],"however,":[251],"promising":[253],"AG.":[258],"Author":[259],"Disclosure":[260],"Employment":[261],"Leadership":[263],"Position":[264],"Consultant":[265],"Advisory":[267],"Role":[268],"Stock":[269],"Ownership":[270],"Honoraria":[271],"Research":[272],"Funding":[273],"Expert":[274],"Testimony":[275],"Other":[276],"Remuneration":[277],"Bayer,":[278,286],"Castle":[279,291],"Biosciences,":[280,292],"Genentech,":[281,294],"Merck,":[282,288],"Novartis,":[283,289,298],"Pfizer,":[284,299],"Schering-Plough":[285,290,300,301],"IMEDEX,":[287],"Celgene,":[293],"Lilly,":[295],"MGI":[296],"Pharma,":[297]},"counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}